{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Andrea Petretto"}, {"accession": "MS:1000589", "name": "contact email", "value": "a.petretto@gmail.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Gaslini Children's Hospital"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Andrea Petretto"}, {"accession": "MS:1000589", "name": "contact email", "value": "andreapetretto@gaslini.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Laboratorio Core Facilities  Gaslini Children's Hospital"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_NT_22_b_031.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_NT_23_b_032.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_NT_27_b_033.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_NT_38_b_034.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_T_22_b_044.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_T_23_b_045.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_T_27_b_046.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD4P_T_38_b_047.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_NT_22_b_051.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_NT_23_b_052.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_NT_27_b_053.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_NT_38_b_054.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_T_22_b_058.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_T_23_b_059.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_T_27_b_060.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_0316_CD8P_T_38_b_061.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC11_CD4p_1A7_2_011.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC11_CD4p_NT_1_006.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC11_CD8p_1A7_4_027.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC11_CD8p_NT_3_020.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC12_CD4p_1A7_6_014.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC12_CD4p_NT_5_007.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC12_CD8p_1A7_8_028.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_BC12_CD8p_NT_7_021.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_IC_CD4p_1A7_10_015.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_IC_CD4p_NT_9_008.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_IC_CD8p_1A7_12_029.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/Quintarelli_OT_1015_IC_CD8p_NT_11_022.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426/CAR_txt.zip"}], "description": "Adoptive T cell therapy with gene-modified T cells expressing chimeric antigen receptor (CAR) is a rapidly growing field of translational medicine and recently has shown dramatic therapeutic success in the treatment of B-cell malignancies. However, challenges to achieve similar response in patients harboring solid tumour are still considerable. To achieve anti-tumor efficacy, these cells must survive, expand and persist after infusion into patients. An important lesson has been derived from clinical trials using CAR technologies: the relevance of the CAR design to enhance signaling and sustain T cell proliferation and survival.  Here, we prove that third generation CARs specific for GD2 antigen incorporating CD28.4-1BB costimulatory domains improves T cell immunotherapy in a neuroblastoma (NB) pre-clinical model, as compared to a CAR with the same specificity but including CD28.OX40 costimulation. Indeed, we test the anti-tumor activity of polyclonal T cells genetically modified with third generation CAR.GD2 incorporating either CD28.4-1BB or CD28.OX40 in frame with the safety switch inducible Caspase 9 (iC9). We prove a significant in vitro and in vivo amelioration of the approach by the presence of 4.1BB signaling in terms of: 1) less T cell exhaustion, 2) lower basal T cell activation, 3) higher in vivo tumor control and 4) T cell persistence. In addition, the fine tuning of T cell culture conditions with the use of IL7 and IL15 show to be synergic with the third generation CAR.GD2 design to optimize CAR T immunotherapy for NB. Our results provide a proof-of-concept for the need to optimize not only CAR construct design but also T cell culture conditions in order to boost T cell activity in vivo.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/06/PXD005426"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD005426"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD005426"}, {"accession": "MS:1001921", "name": "ProteomeXchange accession number version number", "value": "2"}], "instruments": [{"accession": "MS:1001742", "name": "LTQ Orbitrap Velos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Human, CAR, LC-MS/MS, Phosphoproteomics"}, {"accession": "MS:1001926", "name": "curator keyword", "value": "Biomedical"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00394", "name": "acetylated residue"}, {"accession": "MOD:00400", "name": "deamidated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "29872565"}, {"accession": "MS:1002866", "name": "Reference", "value": "Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 2018 7(6):e1433518"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Concert between cytokines and costimulatory domains to optimize chimeric antigen receptor immunotherapy in neuroblastoma model"}